Table 1 Clinical and virological characteristics in LAM-resistant chronic hepatitis B patients
Characteristics | Genotype B | Genotype C | P Valuea |
|---|---|---|---|
Number of patients | 84 | 39 | Â |
Male (%) | 69 (82.1%) | 32 (82.1%) | 0.999 |
Age (years) | 46.0 ± 10.7 | 48.3 ± 10.2 | 0.276 |
rtM204V (%) | 31 (36.9%) | 13 (33.3%) | 0.840 |
rtM204I (%) | 40 (47.6%) | 22 (56.4%) | 0.439 |
rtM204V+rtM204I (%) | 13 (15.5%) | 4 (10.3%) | 0.578 |
rtL180M (%) | 22 (26.2%) | 12 (30.8%) | 0.666 |
rtA181T (%) | 6 (7.1%) | 4 (10.3%) | 0.724 |
HBeAg (%) | 40 (47.6%) | 25 (64.1%) | 0.120 |
AST (IU/L) | 146.5 ± 211.8 | 140.3 ± 222.7 | 0.886 |
ALT (IU/L) | 223.1 ± 341.3 | 181.1 ± 287.6 | 0.506 |
Alpha-fetoprotein (ng/dL) | 4 (0-15) | 3 (0-18) | 0.987 |
HBV-DNA (106 copies/mL) | 14.1 (0.001-16063) | 10.0 (0.0015-1203) | 0.493 |
BCP 1762/1764 mutations (%) | 28 (33.3%) | 31 (79.5%) | < 0.001 |
Precore stop codon mutation (%) | 45 (53.6%) | 11 (28.2%) | 0.0112 |
Pre-S internal deletions (%) | 17 (20.2%) | 15 (38.5%) | 0.0461 |
Cirrhosis | 26 (31.0%) | 14 (35.9%) | 0.680 |
Duration of LAM treatment before inclusion (months) | 13 (6-55) | 14 (6-48) | 0.794 |